We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

150 hedge funds and large institutions have $1.73B invested in Ventyx Biosciences in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 30

16% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 25

4.44% more ownership

Funds ownership: 85.47%89.91% (+4.4%)

3% more funds holding

Funds holding: 146150 (+4)

4% more capital invested

Capital invested by funds: $1.67B → $1.73B (+$59.7M)

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

77% less call options, than puts

Call options by funds: $7.2M | Put options by funds: $31.6M

Holders
150
Holders Change
+4
Holders Change %
+2.74%
% of All Funds
2.36%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.05%
New
29
Increased
70
Reduced
30
Closed
25
Calls
$7.2M
Puts
$31.6M
Net Calls
-$24.4M
Net Calls Change
-$30.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Ensign Peak Advisors
51
Ensign Peak Advisors
Utah
$3.32M
AAA
52
Affinity Asset Advisors
New York
$3.3M -$5.49M -159,312 -61%
PCM
53
Peregrine Capital Management
Minnesota
$3.3M +$3.46M +100,485 New
Hudson Bay Capital Management
54
Hudson Bay Capital Management
Connecticut
$3.13M +$983K +28,515 +43%
Adage Capital Partners
55
Adage Capital Partners
Massachusetts
$3.05M -$14.2M -411,945 -82%
MCMC
56
Matrix Capital Management Company
New Hampshire
$2.95M
Two Sigma Investments
57
Two Sigma Investments
New York
$2.94M +$1.74M +50,340 +128%
Manulife (Manufacturers Life Insurance)
58
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.91M +$709K +20,561 +30%
Swiss National Bank
59
Swiss National Bank
Switzerland
$2.7M +$1.58M +45,700 +125%
Bank of America
60
Bank of America
North Carolina
$2.3M -$258K -7,491 -10%
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
$2.09M +$1.07M +30,952 +94%
AllianceBernstein
62
AllianceBernstein
Tennessee
$2.08M +$1.27M +36,720 +138%
FAM
63
Fred Alger Management
New York
$1.98M -$2.97M -86,297 -59%
UOC
64
UBS O'Connor
Illinois
$1.92M +$394K +11,437 +24%
TLP
65
Tri Locum Partners
New York
$1.9M -$3.28M -95,042 -62%
Jane Street
66
Jane Street
New York
$1.69M +$932K +27,051 +110%
California State Teachers Retirement System (CalSTRS)
67
California State Teachers Retirement System (CalSTRS)
California
$1.6M +$850K +24,666 +102%
Russell Investments Group
68
Russell Investments Group
United Kingdom
$1.56M -$1.01M -29,406 -38%
D.E. Shaw & Co
69
D.E. Shaw & Co
New York
$1.55M -$853K -24,747 -34%
Citigroup
70
Citigroup
New York
$1.5M +$1.25M +36,388 +393%
State of Wisconsin Investment Board
71
State of Wisconsin Investment Board
Wisconsin
$1.47M +$905K +26,249 +140%
AA
72
ALPS Advisors
Colorado
$1.41M +$197K +5,727 +15%
UBS Group
73
UBS Group
Switzerland
$1.4M +$1.46M +42,346 +14,911%
TF
74
TIAA FSB
Florida
$1.37M +$1.44M +41,876 New
Millennium Management
75
Millennium Management
New York
$1.29M +$1.36M +39,407 New

VTYX Hedge Fund Activity: Q2 2023 in Review

150 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q2 2023, worth a combined $1.73B — up 3.6% from $1.67B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new VTYX positions and 25 closed out — a net gain of 4 holders — while 70 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $43.6M. The largest seller was venBio Partners, cutting an estimated $64.6M.

  • 150 institutional investors held Ventyx Biosciences (VTYX) as of Q2 2023, up from 146 in Q1 2023.
  • Funds reported $1.73B of Ventyx Biosciences stock for Q2 2023, up 3.6% quarter-over-quarter.
  • 29 funds opened new Ventyx Biosciences positions in Q2 2023 and 25 closed out, a net change of +4 holders.
  • The largest Ventyx Biosciences buyer in Q2 2023 was T. Rowe Price Associates, an estimated $43.6M added.
  • The largest Ventyx Biosciences seller in Q2 2023 was venBio Partners, an estimated $64.6M sold.

Based on aggregated 13F filings for Q2 2023.